The Global Whole Exome Sequencing Market is expected to reach USD 525.74 million by 2027, growing from USD 219.89 million in 2019, delivering a CAGR of 11.6% through the forecast period. The market is mainly driven by the growing clinical diagnostics application of whole exome sequencing, which enables identifying the underlying genetic cause of several diseases.

The technique is ideal for targeted management of complex conditions like autism spectrum disorder, neuropathy, epilepsy, and other genetic diseases. The whole exome sequencing finds extensive clinical application as it can notably determine the variations in the exon regions while identifying different disease-causing mutations or variants of the disease. The personalized medicine market size is anticipated to be worth USD 131.70 billion by the end of 2027, which will open lucrative growth avenues for the whole exome sequencing market share.

Get a free sample PDF of the report, visit @

https://www.reportsanddata.com/download-free-sample/3588

The growth in the market is also attributed to the increasing prevalence of chronic diseases and growing focus on developing a treatment for unmet medical conditions. However, legal issues linked with the whole exome sequencing technique and lack of skilled professionals may hamper industry growth.

Based on product type, the kits segment is anticipated to contribute significantly towards the whole exome sequencing market share, delivering the highest growth rate through 2027. The growth can be attributed to the frequent use of kits in various research processes and a large number of manufacturers involved in product development, including Illumina, Thermo Fisher Scientific, and others.

In the regional landscape, North America dominates the whole exome sequencing market share and is anticipated to exhibit a notable CAGR through 2027 due to the growing prevalence of chronic diseases like cancer, diabetes, HIV, neurological disorders, along with the rise in overall healthcare expenditure. Europe is estimated to be a major regional ground for the whole exome sequencing market revenue share through 2027 due to a rise in the number of cancer cases and a rise in genome mapping programs.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/3588

Some of the major players dominating the global whole exome sequencing market are BGI, Ambry Genetics, Eurofins Genomics Inc., Life Technologies, Illumina, Inc., and GENEWIZ, Inc. These industry players are adopting several strategies such as acquisitions, mergers, collaborations, new product development, and capacity expansion, thereby supporting the overall growth of the market. Moreover, rising investments by the key industry players for the R&D activities will further bolster the whole exome sequencing market growth over the analysis period.

This report forecasts revenue growth at the global, regional, and country-level and provides an analysis of the industry trends in each of the sub-segments from 2017 to 2027. For the purpose of this study, the whole exome sequencing market is segmented on the basis of product type, technology, application, end-user, and region.

The report states that the Kits segment is anticipated to contribute significantly to the whole exome sequencing market share, delivering the highest growth rate through 2027. The growth can be attributed to the frequent use of kits in various research processes and a large number of manufacturers involved in product development, including Illumina, Thermo Fisher Scientific, and others.

The report also identifies that North America dominates the whole exome sequencing market share and is anticipated to exhibit a notable CAGR through 2027. This growth is due to the growing prevalence of chronic diseases like cancer, diabetes, HIV, neurological disorders, along with the rise in overall healthcare expenditure. Europe is estimated to be a major regional ground for the whole exome sequencing market revenue share through 2027 due to a rise in the number of cancer cases and a rise in genome mapping programs.

Request a customized copy of the report @

https://www.reportsanddata.com/request-customization-form/3588

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs